CSPC PHARMA (01093): High-Selectivity KAT6 Inhibitor (SYH2095 Tablets) Secures Clinical Trial Approval in China

Stock News05-18 20:38

CSPC PHARMA (01093) announced that the innovative Class 1 chemical drug SYH2095 tablets, co-developed with Hangzhou Yingchuang Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) of China to commence clinical trials within the country. Previously, this product also obtained approval from the U.S. Food and Drug Administration (FDA) to proceed with clinical trials in the United States in April 2026. SYH2095 is a novel lysine acetyltransferase 6 (KAT6) inhibitor, belonging to a class of epigenetic anti-cancer drugs. It exerts its anti-tumor effects by inhibiting histone lysine acetylation, blocking open chromatin, and subsequently regulating cell cycle, estrogen receptor expression, and cellular senescence pathways. It is intended for the treatment of advanced malignant tumors. Preclinical studies indicate that the product demonstrates highly potent and selective inhibition of KAT6, significantly suppressing tumor growth, and exhibits favorable pharmacokinetic properties and safety. Currently, no drugs targeting this same mechanism are approved for marketing globally, highlighting the substantial clinical development value of this product.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166973511?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-18 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166973511","market":"fut","top_or_hot":-1,"title":"CSPC PHARMA (01093): High-Selectivity KAT6 Inhibitor (SYH2095 Tablets) Secures Clinical Trial Approval in China","media":"Stock News","content":"<p>CSPC PHARMA (01093) announced that the innovative Class 1 chemical drug SYH2095 tablets, co-developed with Hangzhou Yingchuang Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) of China to commence clinical trials within the country. Previously, this product also obtained approval from the U.S. Food and Drug Administration (FDA) to proceed with clinical trials in the United States in April 2026. SYH2095 is a novel lysine acetyltransferase 6 (KAT6) inhibitor, belonging to a class of epigenetic anti-cancer drugs. It exerts its anti-tumor effects by inhibiting histone lysine acetylation, blocking open chromatin, and subsequently regulating cell cycle, estrogen receptor expression, and cellular senescence pathways. It is intended for the treatment of advanced malignant tumors. Preclinical studies indicate that the product demonstrates highly potent and selective inhibition of KAT6, significantly suppressing tumor growth, and exhibits favorable pharmacokinetic properties and safety. Currently, no drugs targeting this same mechanism are approved for marketing globally, highlighting the substantial clinical development value of this product.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC PHARMA (01093): High-Selectivity KAT6 Inhibitor (SYH2095 Tablets) Secures Clinical Trial Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC PHARMA (01093): High-Selectivity KAT6 Inhibitor (SYH2095 Tablets) Secures Clinical Trial Approval in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-18 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC PHARMA (01093) announced that the innovative Class 1 chemical drug SYH2095 tablets, co-developed with Hangzhou Yingchuang Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) of China to commence clinical trials within the country. Previously, this product also obtained approval from the U.S. Food and Drug Administration (FDA) to proceed with clinical trials in the United States in April 2026. SYH2095 is a novel lysine acetyltransferase 6 (KAT6) inhibitor, belonging to a class of epigenetic anti-cancer drugs. It exerts its anti-tumor effects by inhibiting histone lysine acetylation, blocking open chromatin, and subsequently regulating cell cycle, estrogen receptor expression, and cellular senescence pathways. It is intended for the treatment of advanced malignant tumors. Preclinical studies indicate that the product demonstrates highly potent and selective inhibition of KAT6, significantly suppressing tumor growth, and exhibits favorable pharmacokinetic properties and safety. Currently, no drugs targeting this same mechanism are approved for marketing globally, highlighting the substantial clinical development value of this product.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B031HY20.USD","symbol_name":"FSSA CHINA GROWTH \"I\" (USD) INC","start_time":0,"source_url":"","article_id":"1166973511","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166973511","pubTimestamp":1779107911,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSPC PHARMA (01093) announced that the innovative Class 1 chemical drug SYH2095 tablets, co-developed with Hangzhou Yingchuang Pharmaceutical Technology Co., Ltd., has received approval from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","BK1191":"制药","IE0008368742.USD":"首域中国增长基金I Acc","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","BK1515":"抗疫概念","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK1521":"挪威政府全球养老基金持仓","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","01093":"石药集团","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC"},"translate_title":"石药集团（01093）：高选择性KAT6抑制剂（SYH2095片）获中国临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC PHARMA (01093) announced that the innovative Class 1 chemical drug SYH2095 tablets, co-developed with Hangzhou Yingchuang Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) of China to commence clinical trials within the country. Previously, this product also obtained approval from the U.S. Food and Drug Administration (FDA) to proceed with clinical trials in the United States in April 2026. SYH2095 is a novel lysine acetyltransferase 6 (KAT6) inhibitor, belonging to a class of epigenetic anti-cancer drugs. It exerts its anti-tumor effects by inhibiting histone lysine acetylation, blocking open chromatin, and subsequently regulating cell cycle, estrogen receptor expression, and cellular senescence pathways. It is intended for the treatment of advanced malignant tumors. Preclinical studies indicate that the product demonstrates highly potent and selective inhibition of KAT6, significantly suppressing tumor growth, and exhibits favorable pharmacokinetic properties and safety. Currently, no drugs targeting this same mechanism are approved for marketing globally, highlighting the substantial clinical development value of this product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166973511","isCrawlerRequest":true}